Nektar Therapeutics
(NASDAQ : NKTR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Loading NKTR News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.78%71.011.0%$662.14m
AMGNAmgen Inc.
0.57%154.670.8%$509.58m
CELGCelgene Corporation
-0.85%112.661.0%$466.03m
ARIAARIAD Pharmaceuticals, Inc.
0.21%23.7516.4%$442.07m
BIIBBiogen Inc.
0.11%280.661.0%$398.14m
REGNRegeneron Pharmaceuticals, Inc.
-0.23%362.562.5%$365.69m
ALXNAlexion Pharmaceuticals, Inc.
-1.77%131.972.5%$347.73m
ILMNIllumina, Inc.
-0.52%159.743.8%$229.47m
CLVSClovis Oncology, Inc.
2.07%58.2917.9%$160.24m
INCYIncyte Corporation
-0.26%117.222.2%$158.22m
VRTXVertex Pharmaceuticals Incorporated
0.57%81.372.1%$144.14m
TSROTESARO, Inc.
-1.94%147.0015.0%$106.77m
IONSIonis Pharmaceuticals, Inc.
0.58%46.978.9%$101.63m
SRPTSarepta Therapeutics, Inc.
-4.59%32.6616.8%$101.57m
BMRNBioMarin Pharmaceutical Inc.
-1.78%84.624.9%$95.71m

Company Profile

Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its products includes of drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. It provides small molecule drugs, peptides and other potential biologic drug candidates. It's drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. The company was founded in 1990 and is headquartered in San Francisco, CA.